Barriers to PARP Inhibitors Plus Androgen Receptor-Targeted Agents in Earlier Treatment Settings

By Tanya Dorff, MD - Last Updated: February 13, 2023

Tanya Dorff, MD, Associate Professor in the Department of Medical Oncology & Therapeutics Research, and Section Chief of the Genitourinary Disease Program, City of Hope Comprehensive Cancer Center, shares the barriers to utilizing PARP inhibitors plus androgen receptor-targeted agents in the castration-sensitive or upfront prostate cancer settings.

View Dr. Dorff’s other comments on treatment for prostate cancer, including PROpel and MAGNITUDE Trials for mCRPC and Combination Versus Sequential Therapy for mCRPC.

Advertisement
Advertisement